Risk Factors for Recurrent VTE in Cancer with Dr Faizan Khan

Send us a textIn this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of factor XI may reduce post-operative venous thromboembolism with potentially lower bleeding risk than current anticoagulants.Dr. Weitz explains the distinct mechanisms of the two antibodies, the role of factor XII-mediated activation in post-operative VTE, key efficacy and safety outcomes, and how these early-phase studies set the stage for ongoing phase-2 and phase-3 trials—including ROXI-CATH, ROXI-Aspirin, and emerging AF and stroke-prevention research.This episode is essential listening for clinicians interested in the rapidly evolving landscape of anticoagulation and next-generation therapies that may offer safer options for patients undergoing orthopedic surgery and beyond.Read the full Lancet publication by clicking on the link below and explore more thrombosis resources at thrombosiscanada.ca.Become a Thrombosis Champion, be a monthly donor at https://thrombosiscanada.ca/donatehttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02097-5/abstract [Note: full access requires a subscription]Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textDiagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their findings mean for the safe use of D-dimer and anticoagulation status in clinical practice.Reference:Mai, V., Martens, E. S., Righini, M., Schulman, S., Thiruganasambandamoorthy, V., Kahn, S. R., ... & Le Gal, G. (2025). Performance of clinical decision rules in patients presenting with suspected recurrent venous thromboembolism: a multicenter prospective cohort study. Journal of Thrombosis and Haemostasis.https://www.sciencedirect.com/science/article/abs/pii/S1538783625004088Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textThis episode reviews findings from a cross-sectional study at SickKids on health literacy in pediatric VTE patients and caregivers (Res Pract Thromb Haemost, 2025). Among 101 participants, 74% of adolescents and 59% of parents/caregivers demonstrated low general health literacy using REALM, HAS-A, and eHEALS instruments. Communication with providers was the most affected domain, and fewer than half of participants were satisfied with their thrombosis knowledge. Adolescents frequently overestimated their understanding, underscoring the need for simplified educational resources and a “universal precautions” approach to health literacy in pediatric thrombosis care.AboutKidsHealth Thrombosis Hub: https://www.aboutkidshealth.ca/thrombosisBastas, D., Mancini, A., Wong, G., Brandão, L. R., Mukaj, S., Vincelli, J., ... & Avila, L. (2025). Health literacy in pediatric thrombosis: a landscape analysis. Research and Practice in Thrombosis and Haemostasis, 9(1), 102653.Publication Link: https://www.rpthjournal.org/article/S2475-0379%2824%2900348-0/fulltextSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode, Dr. Laura Avila and Jennifer Vincelli discuss their Blood publication on long-term outcomes of pediatric pulmonary embolism. Among 150 patients, ~30% had incomplete PE resolution and 9% experienced recurrence, but persistent sequelae were rare. True post-PE syndrome occurred in <9%, with only one case of CTEPH. The findings highlight the value of structured follow-up, attention to underlying conditions, and promoting physical activity to counter deconditioning.To access the publication use this URL: https://thrombosiscan.info/CLOT-CONVO-46Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of CLOT Conversations, we discuss the newly developed Orthopedic Surgery VTE Thromboprophylaxis Guideline Summary. Dr. Marc Carrier, a hematologist and key author, highlights the need for a multidisciplinary approach in managing venous thromboembolism (VTE) risks, particularly in orthopedic surgery. The conversation covers preoperative risk assessments, options for pharmacological and mechanical thromboprophylaxis, and the evolving landscape of surgical techniques that influence thrombosis risk. The episode emphasizes the importance of providing clinicians with practical tools to effectively navigate VTE prevention.Access the full review paper here: https://thrombosiscanada.ca/uploads/publications/WhitePapers/TC135_VTE_Whitepaper_v4.pdfSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of CLOT Conversations, experts discuss recent research on cancer-associated thrombosis and the predictors of recurrent venous thromboembolism (VTE) and anticoagulant-related bleeding. Dr. Faizan Khan, a leading researcher in the field, explains the results of their study that aimed to offer a comprehensive understanding of the prognostic factors associated with these risks. Hear what he says about the evidence for associations of several patient- and cancer-related factors, and the risk of recurrent VTE. This research is expected to inform clinical practice by promoting a more individualized approach to anticoagulant management in cancer patients.Reference: Khan, F., Tritschler, T., Marx, C. E., Lanting, V., Rochwerg, B., Tran, A., ... & Carrier, M. (2025). Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. European Heart Journal, ehaf453.https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf453/8170116?login=falseSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textDid you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable.Jordan walks us through surprising insights from their analysis of over 120 studies: 🔹 Why gastroesophageal, ovarian, and brain cancers top the list for clot risk 🔹 What the data reveals about sex-based differences 🔹 How global gaps in reporting may be leaving patients behind 🔹 And what a cancer survivor told her that changed how she views her workThis isn’t just another research summary, it’s a conversation about saving lives by recognizing the often-overlooked danger of cancer-associated thrombosis. If you care about improving outcomes in oncology or want to understand the real-world impact of VTE in cancer care, this is a must-listen.To access the ISTH Common Data Elements mentioned in this episode: https://isth.breakthrough.healthcare/To access the Thrombosis Canada Cancer-Associated Thrombosis resources for patients: https://thrombosiscanada.ca/cancerTo access the publication: https://www.sciencedirect.com/science/article/abs/pii/S1877782125000232Ref: Jordan Harry, Regan Bucciol, Deirdre Finnigan, Hussein Hashem, Ahmad Araki, Maha Othman, The incidence of venous thromboembolism by type of solid cancer worldwide: A systematic review, Cancer Epidemiology, Volume 95, 2025, 102764,ISSN 1877-7821, https://doi.org/10.1016/j.canep.2025.102764.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode we speak with the three competitors from the INVENT Dragons' Den competition 2025. Hear from the researchers about their research plans that they presented in the hopes of being awarded $40,000 in funding. The researchers were: Dr Francis Couturaud (ETHER Study), Dr Leslie Skeith (PARTUM Study) and Dr Emma Leitinger (BUTTERFLY Study).Participating INVENT network members include CanVECTOR (Canada), CURES Network (China), INNOVTE (France), INViTE (Ireland), DTN (Netherlands), Center for Thrombosis and Hemostasis (Germany), TRIP (Italy), Norwegian Thrombosis Network, THANZ (Australia and New Zealand), VENUS (USA), and UK-TrEN (United Kingdom). For more information about INVENT go to https://www.invent-vte.com/Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Send us a textIn this episode of CLOT Conversations, Dr. Gregoire Le Gal, University of Ottawa, in an interview with Dr Vicky Mai, shares insights from his groundbreaking study on age-adjusted D-dimer cutoffs for diagnosing deep vein thrombosis (DVT). Previously validated for pulmonary embolism (PE), this new approach significantly improves DVT diagnostics. By adjusting D-dimer thresholds based on patient age, the study found a safe and reliable method to rule out DVT without reliance on additional imaging. Though results showed a smaller incremental increase in negative D-dimer results compared to PE, the safety of the approach was confirmed. This research simplifies DVT diagnostics, making it easier for clinicians, especially in emergency settings.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada